Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer (CAPRI-3 GOIM)

CAPRI-3 GOIM Study: Phase 3 Clinical Study to Evaluate the Use of Continuing Cetuximab Treatment Beyond First Line Progression in Molecular Selected Metastatic Colorectal Cancer Patients.

The goal of this Phase 3 clinical trial is to evaluate whether continuing cetuximab treatment beyond first-line progression can improve outcomes in patients with metastatic colorectal cancer whose tumors are RAS and BRAF wild-type. The study will compare the effectiveness of chemotherapy given together with cetuximab versus chemotherapy given together with bevacizumab. Researchers aim to determine whether cetuximab continuation improves tumor response, progression-free survival, overall survival, and safety in this patient population.

Eligible participants are adults with metastatic colorectal cancer who have previously responded to first-line treatment with chemotherapy combined with an anti-EGFR antibody. Before starting therapy, patients will undergo molecular testing using liquid biopsy to confirm tumor characteristics. They will then receive chemotherapy with either cetuximab or bevacizumab every two weeks, and their disease will be monitored regularly with CT or MRI scans, laboratory tests, and clinical evaluations. During the study, patients will also provide biological samples for translational research.

This trial will enroll about 360 patients across sites in Italy and Spain and is designed to provide new evidence on whether cetuximab continuation beyond first-line treatment can offer a meaningful clinical benefit compared with standard therapy.

Study Overview

• Status: Recruiting
• Conditions: Metastatic Colorectal Cancer (mCRC)
• Intervention / Treatment: Drug: Erbitux (Cetuximab); Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin); Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); Drug: Bevacizumab

Detailed Description

Metastatic colorectal cancer (mCRC) is one of the most common and lethal cancers worldwide. Despite progress with chemotherapy and targeted therapies, many patients experience disease progression after first-line treatment. In recent years, drugs targeting the Epidermal Growth Factor Receptor (EGFR), such as cetuximab, have shown significant benefit in patients with RAS and BRAF wild-type tumors. However, it remains unclear whether continuing cetuximab beyond progression, while changing the chemotherapy backbone, can provide additional benefit compared to switching to an alternative targeted treatment.

The CAPRI-3 study is a randomized, multicenter, open-label Phase 3 clinical trial designed to address this question. The study will enroll approximately 360 adult patients with metastatic colorectal cancer in Italy and Spain. All participants must have tumors that are RAS and BRAF wild-type, as well as PIK3CA and EGFR extracellular domain wild-type and HER2 non-amplified, as determined by next-generation sequencing on liquid biopsy at the time of screening. Eligible patients will have previously received a first-line regimen with chemotherapy plus an anti-EGFR antibody (cetuximab or panitumumab) and achieved either a complete or partial response, or prolonged stable disease, before disease progression.

Patients will be randomized in a 1:1 ratio to receive a standard chemotherapy doublet (FOLFOX or FOLFIRI, depending on the regimen used in the first line) combined either with cetuximab (experimental arm) or with bevacizumab (control arm). Treatment will be continued until disease progression, unacceptable toxicity, or withdrawal of consent. Tumor response will be assessed according to RECIST 1.1 criteria by independent central review.

The primary endpoint of the study is objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), and safety profile assessed according to NCI CTCAE version 5.0. Exploratory objectives include biomarker and translational research, involving the collection and analysis of tumor tissue, blood, and stool samples to better understand resistance mechanisms and the role of the gut microbiome in treatment response.

This study builds on promising results from the earlier CAPRI and CAPRI-2 trials, which suggested that continuing cetuximab in second-line therapy may improve patient outcomes. If successful, CAPRI-3 could establish cetuximab continuation beyond first-line progression as a new treatment option for a large proportion of molecularly selected patients with metastatic colorectal cancer.

• Study Type: Interventional
• Enrollment (Estimated): 480
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Fortunato Ciardiello; Phone Number: 0815666760; Email: fortunato.ciardiello@unicampania.it
• Study Contact Backup: Name: Stefania Napolitano; Email: stefania.napolitano@unicampania.it

Study Locations

• Italy
  • Ancona, Italy
    • Not yet recruiting
    • A.O.U. Ospedali Riuniti
    • Principal Investigator: Rossana Berardi
  • Avellino, Italy
    • Not yet recruiting
    • AORN S. Giuseppe Moscati
    • Principal Investigator: Giuseppe Santabarbara
  • Aviano, Italy
    • Not yet recruiting
    • Centro di Riferimento Oncologico (C.R.O.) IRCCS
    • Principal Investigator: Michela Guardascione
  • Bari, Italy
    • Not yet recruiting
    • IRCCS Istituto Tumori "Giovanni Paolo II"
    • Principal Investigator: Nicola Silvestris
  • Brescia, Italy
    • Not yet recruiting
    • Fondazione Poliambulanza Istituto Ospedaliero
    • Principal Investigator: Michela Libertini
  • Castellana Grotte, Italy
    • Not yet recruiting
    • Ospedale IRCCS 'Saverio de Bellis'
    • Principal Investigator: Claudio Lotesoriere
  • Catania, Italy
    • Not yet recruiting
    • Nome EnteA.R.N.A.S. Garibaldi - P.O. Garibaldi-Nesima
    • Principal Investigator: Roberto Bordonaro
  • Catanzaro, Italy
    • Not yet recruiting
    • Azienda Ospedaliero-Universitaria Renato Dulbecco
    • Principal Investigator: Pierosandro Tagliaferri
  • Florence, Italy
    • Not yet recruiting
    • A.O.U. Careggi
    • Principal Investigator: Lorenzo Antonuzzo
  • Lecce, Italy
    • Not yet recruiting
    • P.O. 'Vito Fazzi'
    • Principal Investigator: Silvana Leo
  • Meldola, Italy
    • Not yet recruiting
    • Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'
    • Principal Investigator: Alessandro Passardi
  • Milan, Italy
    • Not yet recruiting
    • ASST Grande Ospedale Metropolitano Niguarda
    • Principal Investigator: Andrea Sartore Bianchi
  • Milan, Italy
    • Not yet recruiting
    • Fondazione IRCCS Istituto Nazionale dei Tumori
    • Principal Investigator: Filippo Pietrantonio
  • Milan, Italy
    • Not yet recruiting
    • Istituto Europeo di Oncologia
    • Principal Investigator: Maria Giulia Zampino
  • Mirabella Eclano, Italy
    • Not yet recruiting
    • Casa di Cura Villa Maria
    • Principal Investigator: Antonio Febbraro
  • Napoli, Italy
    • Not yet recruiting
    • A.O.U. Federico II
    • Principal Investigator: Chiara Carlomagno
  • Napoli, Italy
    • Recruiting
    • A.O.U. dell'Università degli studi della Campania 'Luigi Vanvitelli'
    • Principal Investigator: Fortunato Ciardiello
  • Napoli, Italy
    • Not yet recruiting
    • IRCCS I.N.T. 'Fondazione G. Pascale'
    • Principal Investigator: Antonio Avallone
  • Padua, Italy
    • Not yet recruiting
    • Istituto Oncologico Veneto IRCCS
    • Principal Investigator: Francesca Bergamo
  • Palermo, Italy
    • Not yet recruiting
    • ARNAS Civico - Di Cristina-Benfratelli - P. O. 'Civico e Benfratelli'
    • Principal Investigator: Marco Messina
  • Palermo, Italy
    • Not yet recruiting
    • Casa di cura Macchiarella
    • Principal Investigator: Alfredo Colombo
  • Pisa, Italy
    • Not yet recruiting
    • A.O.U. Pisana
    • Principal Investigator: Chiara Cremolini
  • Reggio Emilia, Italy
    • Not yet recruiting
    • Azienda USL IRCCS Di Reggio Emilia
    • Principal Investigator: Maria Banzi
  • Roma, Italy
    • Not yet recruiting
    • Fondazione Policlinico Universitario 'Agostino Gemelli' IRCCS
    • Principal Investigator: Giampaolo Tortora
  • Rozzano, Italy
    • Not yet recruiting
    • IRCCS Istituto Clinico Humanitas
    • Principal Investigator: Alberto Puccini
  • San Giovanni Rotondo, Italy
    • Not yet recruiting
    • Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
    • Principal Investigator: Tiziana Pia Latiano
  • Sassari, Italy
    • Not yet recruiting
    • A.O.U. Sassari
    • Principal Investigator: Alessio Cogoni
  • Statte, Italy
    • Not yet recruiting
    • Ospedale San Giuseppe Moscati
    • Principal Investigator: Salvatore Pisconti
  • Tricase, Italy
    • Not yet recruiting
    • A.O. 'Pia Fondazione Cardinale G.Panico'
    • Principal Investigator: Emiliano Tamburini
  • Veneto, Italy
    • Not yet recruiting
    • IRCCS Ospedale Sacro Cuore Don Calabria
    • Principal Investigator: Stefania Gori
• Spain
  • Barcelona, Spain
    • Not yet recruiting
    • Hospital del Mar
    • Principal Investigator: Clara Montagut Viladot
  • Barcelona, Spain
    • Not yet recruiting
    • Hospital Universitari Vall d´Hebrón
    • Principal Investigator: Francesc Salvà Ballabrera
  • Cartagena, Spain
    • Not yet recruiting
    • Hospital General Universitario Santa Lucía
    • Principal Investigator: Paola Pimentel Càceres
  • Córdoba, Spain
    • Not yet recruiting
    • Hospital Universitario Reina Sofía
    • Principal Investigator: Maria Jose Ortiz Morales
  • Granada, Spain
    • Not yet recruiting
    • Hospital Universitario Virgen de las Nieves
    • Principal Investigator: Encarnaciòn Gonzàles Flores
  • L'Hospitalet de Llobregat, Spain
    • Not yet recruiting
    • Instituto Catalán de Oncología. Hospital Duran i Reynals
    • Principal Investigator: Cristina Santos Vivas
  • Madrid, Spain
    • Not yet recruiting
    • Hospital Universitario 12 de Octubre
    • Principal Investigator: Cristina Grávalos Castro
  • Madrid, Spain
    • Not yet recruiting
    • Hospital Universitario Gregorio Maranon
    • Principal Investigator: Pilar Garcia Alfonso
  • Málaga, Spain
    • Not yet recruiting
    • Hospital Universitario Regional de Malaga
    • Principal Investigator: Julia Alcaide Garcìa
  • Pamplona, Spain
    • Not yet recruiting
    • Hospital Universitario de Navarra
    • Principal Investigator: Ruth Vera Garcìa
  • Santander, Spain
    • Not yet recruiting
    • Hospital Universitario Marqués de Valdecilla
    • Principal Investigator: Fernando Rivera Herrero

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Histologically proven diagnosis of colorectal adenocarcinoma.
2. Diagnosis of metastatic disease.
3. Efficacy of a first line therapy containing anti-EGFR drug with a major response achieved (i.e. complete or partial response according to RECIST criteria v1.1) or a prolonged (at least 6 months) stable disease.
4. Progression to first line therapy.
5. RAS and BRAF wild-type status of FFPE analysis of primary colorectal cancer and/or related metastasis.
6. RAS (NRAS and KRAS exon 2,3 and 4), BRAFV600E, PIK3CA, EGFR ECD wild-type and HER2 not amplified in liquid biopsy at the time of screening (according to NGS, Foundation/Roche).
7. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST criteria, vers.1.1).
8. Male or female patients ≥ 18 years of age.
9. ECOG Performance Status 0-1.

10. Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment as defined by the following parameters:

    Bone marrow:

    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • Hemoglobin (Hgb) ≥ 9 g/dL
    • Platelets ≥ 100 x 109/L

    Liver function:

    • Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and ALT (SGPT) ≤ 2.5 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ≤ 5 x ULN

    Renal function:

    • Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min

11. If female and of childbearing potential*, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment.

    *A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

12. If female and of childbearing potential, or if male, agreement to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier method), during the study and until at least 6 months after last dose of study treatment administration, based on the judgment of the Investigator or a designated associate.
13. Signed informed consent obtained before screening.

Exclusion Criteria:

1. Any contraindication to the use of cetuximab, bevacizumab, Irinotecan, 5-FU, oxaliplatin, folic acid.
2. Active uncontrolled infections, active disseminated intravascular coagulation or history of interstitial lung disease.
3. Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix.
4. Pregnancy (exclusion to be ascertained by a beta hCG test).
5. Breastfeeding.
6. Fertile women (<2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.
7. Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or without stenting within the past 12 months before inclusion in the study, Grade III or IV heart failure (NYHA classification).
8. Cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin.
9. Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study.
10. Participation in a clinical study or experimental drug treatment within 30 days prior to study inclusion or during participation in the study.
11. Known or clinically suspected brain metastases.
12. History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhea.
13. Severe, non-healing wounds, ulcers or bone fractures.
14. Marked proteinuria (nephrotic syndrome).
15. Known DPD deficiency (specific screening not required).
16. Known history of alcohol or drug abuse.
17. A significant concomitant disease which, in the investigating physician's opinion, rules out the patient's participation in the study.
18. Absent or restricted legal capacity.
19. Patients with known dMMR or MSI-H tumors who are eligible for approved immune checkpoint inhibitor therapy will be excluded from the trial, unless ICI therapy is contraindicated or declined by the patient. This ensures alignment with current standard of care.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ARM A Chemo-doublet (FOLFIRI or FOLFOX) + Cetuximab; This arm is for participants with RAS/BRAF wild-type metastatic colorectal cancer who have progressed after first-line anti-EGFR therapy. They will receive a second-line chemotherapy regimen (either FOLFIRI or FOLFOX) in combination with cetuximab. The objective is to evaluate the efficacy of continuing cetuximab beyond progression.	Drug: Erbitux (Cetuximab); This is an anti-EGFR monoclonal antibody administered in combination with chemotherapy. The dose is 500 mg/m² administered every 14 days as a 120-minute intravenous infusion on cycle 1 day 1, infusion rate not faster than 5mg/min.; Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin); This is a standard chemotherapy regimen containing irinotecan, fluorouracil, and folinic acid. It is used as the backbone chemotherapy in both study arms. The dose includes 200 mg/m2 L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion every 14 days.; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); This is a standard chemotherapy regimen containing folinic acid, oxaliplatin, and fluorouracil. It is used as the backbone chemotherapy in both study arms. The dose includes 200 mg/m2 L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.
Active Comparator: ARM B Chemo-doublet (FOLFIRI or FOLFOX) + Bevacizumab; This arm is for participants with RAS/BRAF wild-type metastatic colorectal cancer who have progressed after first-line anti-EGFR therapy. They will receive a second-line chemotherapy regimen (either FOLFIRI or FOLFOX) in combination with bevacizumab. This arm serves as the control group to compare the outcomes with the experimental arm.	Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin); This is a standard chemotherapy regimen containing irinotecan, fluorouracil, and folinic acid. It is used as the backbone chemotherapy in both study arms. The dose includes 200 mg/m2 L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion every 14 days.; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); This is a standard chemotherapy regimen containing folinic acid, oxaliplatin, and fluorouracil. It is used as the backbone chemotherapy in both study arms. The dose includes 200 mg/m2 L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.; Drug: Bevacizumab; This is an anti-VEGF monoclonal antibody used as an active comparator in the control arm of the study. The dose is 5 mg/kg of body weight, administered every 14 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	The primary outcome is the Objective Response Rate, which will be evaluated according to the RECIST criteria 1.1. The study aims to determine if the continuous use of cetuximab in the experimental arm results in a superior Response Rate compared to the control arm with bevacizumab.	From date of randomization until the date of first documented progression or date of death from any cause, or study completion whichever came first, assessed until 48 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	Time from randomization until death due to any cause. Patients alive at last follow-up will be censored at that date.	From randomization (Day 0) until death from any cause, assessed through study completion (up to 36 months of survival follow-up)
Progression-Free Survival (PFS)	Time from randomization until the date of first documented disease progression, as assessed by central independent review according to RECIST 1.1 criteria, or death from any cause, whichever occurs first.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months from last patient randomized.
Safety Profile: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	The safety profile of the trial drugs as measured by the incidence of AEs, SAEs, clinical laboratory assessments, vital signs, physical examination, ECG parameters, and ECOG PS.	From first treatment administration until 30 days after the last dose.

Collaborators and Investigators

• Sponsor: University of Campania Luigi Vanvitelli
• Investigators: Principal Investigator: Fortunato Ciardiello, A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli"

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2025
• Primary Completion (Estimated): October 1, 2030
• Study Completion (Estimated): October 1, 2030

Study Registration Dates

• First Submitted: September 30, 2025
• First Submitted That Met QC Criteria: February 4, 2026
• First Posted (Actual): February 5, 2026

Study Record Updates

• Last Update Posted (Actual): February 5, 2026
• Last Update Submitted That Met QC Criteria: February 4, 2026
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colonic Diseases; Colorectal Neoplasms; Amino Acids, Peptides, and Proteins; Proteins; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Camptothecin; Alkaloids; Enzymes and Coenzymes; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Coordination Complexes; Pyrimidines; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Uracil; Pyrimidinones; Coenzymes; Oxaliplatin; Bevacizumab; Irinotecan; Cetuximab; Fluorouracil; Leucovorin; Folfox protocol
• Other Study ID Numbers: CAPRI-3- GOIM Study

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No